Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. - sprookjes - yvandenbroek - TriplyDB

Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.

Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.

http://www.wikidata.org/entity/Q37354846

about

Iron Oxide as an MRI Contrast Agent for Cell Tracking Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.Inhibition of SUR1 decreases the vascular permeability of cerebral metastases.Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.USPIO-Enhanced MRI Neuroimaging: A Review.Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review Perfusion and permeability MR imaging of gliomas.Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors.The paradoxical effect of bevacizumab in the therapy of malignant gliomas.Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard High-field small animal magnetic resonance oncology studies.Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound.Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.Noninvasive targeting delivery and in vivo magnetic resonance tracking method for live apoptotic cells in cerebral ischemia with functional Fe2O3 magnetic nanoparticles Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle.Uses of nanoparticles for central nervous system imaging and therapy.MR molecular imaging of tumor vasculature and vascular targets.MRI & MRS assessment of the role of the tumour microenvironment in response to therapy.Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging of cancer.Potential of glyburide to reduce intracerebral edema in brain metastases.Emerging applications for ferumoxytol as a contrast agent in MRI.Nanomaterial applications in multiple sclerosis inflamed brain.What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.

P2860

Q26781657-F71D0046-ADB5-465E-AA41-E3BFE83C9A84 Q26853308-609BA240-3595-492D-8A83-620385610377 Q28066044-25E50367-5231-4D56-92C9-A18BDCBE1D01 Q30234702-DDD2D9BA-96BF-4722-AD66-C18E77E91858 Q30273936-60FA2547-CEC5-4380-BE4D-577D64CCAFD9 Q30579847-4F2DC7F7-099C-4746-93BD-9F2812D83BB7 Q30653828-B84FACFF-5DD0-4CDC-BC7E-AE5AAC7AE8C7 Q30859319-3E08DEB6-0E70-4F20-9635-51A8BFD1F909 Q30930526-A0A33523-4E04-44A1-9A0D-C067BA2BD22E Q30934034-2A4FE497-C352-4D61-B818-784384E1958D Q31051172-03E11B1A-1C1F-42EF-8BBE-7CD5C8FABE67 Q33390234-7F01C152-0635-4716-BD5F-D8A8B310859A Q33503551-9AD000B0-5142-430F-A444-1BA6B020A471 Q33788231-AD89E3F0-3806-4DB7-96DC-FB1E7F800C99 Q33933312-58C2D35D-9ECA-4F24-850C-39A56FCEBE52 Q34480549-737CE0B3-6BAA-4DC7-AB66-BCF8F62BAFE4 Q34517492-264BA0C8-F5AB-4B52-AD95-764DBB9C7931 Q34536275-67691523-C2BA-47AB-9A17-3942DDDBB616 Q34722530-28613BC3-1A8D-41F7-BC3F-6011F16344EB Q35035576-95FE616D-350F-4B79-B94E-C61CE2C4C558 Q35090720-DCE798FA-C57B-44EB-A28A-BD08ACE4852A Q35312455-555474A8-928D-47C7-9080-8D158E3D7CB0 Q35561003-F97ECCF4-47DB-40D8-A055-4FC512A92339 Q35670736-1EE1C27A-74BC-4629-B973-13CC1283CE37 Q35687164-8FEC3F1F-8971-405F-9645-06359960C660 Q35759617-6C528CCC-90B2-4661-81FA-1A5EA10CF450 Q35842769-102EC62E-1AE3-45C0-B1F4-F052D2B9EFD6 Q36235508-571106FF-4C70-4909-84CA-E83BFF755477 Q36500372-A8614923-DB38-430F-8C0A-D90141E54A11 Q36679311-986842A9-D89D-4E3B-8994-6F192B5A5DA4 Q36731879-9C2C5A84-9066-4AB4-A577-7A5EA2AEFF1B Q36842826-E51095C2-0EF1-47DE-B24B-CAA59220BFC3 Q37555829-D02A8702-9892-418F-BDD0-B65E9D8AC707 Q37784288-1F26FC0A-6FE5-4D35-AF34-AB94AFE1B1FF Q37875004-F179DADC-7E2A-4B49-B685-371A37F5BAB2 Q37971329-604B37BD-3ADA-4AF2-9B46-94DDFFEDE3A8 Q38189496-7F5CDC7F-E424-46EA-9DF8-169D2121FFA0 Q38224182-B4488551-B864-4AE7-9F97-BE0A5931259A Q38330408-6F634745-AC09-4030-897E-79BBD2539385 Q38790910-FA1A37B1-CF68-484F-8CA7-55FAA89A387B

P2860

Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.

http://www.wikidata.org/entity/Q37354846

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dynamic MRI using iron oxide n ...... d treatment in a glioma model.

@en

Dynamic MRI using iron oxide n ...... d treatment in a glioma model.

@nl

type

label

Dynamic MRI using iron oxide n ...... d treatment in a glioma model.

@en

Dynamic MRI using iron oxide n ...... d treatment in a glioma model.

@nl

prefLabel

Dynamic MRI using iron oxide n ...... d treatment in a glioma model.

@en

Dynamic MRI using iron oxide n ...... d treatment in a glioma model.

@nl

P1433

Q37354846-19C41BAD-83B7-409C-B246-B884D6EB899A

P1476

Q37354846-60A86DFC-0658-499A-8447-9BC88F4D95E8

P2093

Q37354846-01288603-288E-458D-B92E-EF3B5FD45A9E

Q37354846-28F75887-9CEE-446F-9D99-FA5BDA137C77

Q37354846-5280AB76-9DDB-47E5-A409-11E9F81DC78F

Q37354846-576A49CE-94E3-4D67-B092-2E93BD67D133

Q37354846-64713185-FE3D-4344-9718-0F4C53908B9D

Q37354846-698E7093-9F11-4D09-83D2-90F7CF4CC530

Q37354846-F96D3C13-4358-4146-8478-F473E6D288F4

P2860

Q37354846-0E1737DF-E97B-4BAB-8831-0F6E668195D3

Q37354846-150F2A50-964D-43BA-BD9E-45905D1CD1C0

Q37354846-1BE7A0E0-4B38-4EF1-B91A-6D13951146BC

Q37354846-1E3F9F23-CABD-4DCB-A59E-51309F293A55

Q37354846-1F463C21-B9B0-4571-89E2-6C45B0292EFF

Q37354846-219D53ED-72B3-471B-98DE-50289AF4950B

Q37354846-2ADC0EE2-FB2D-4627-A186-1B8D671E9097

Q37354846-321B0331-C096-44B4-AA90-7C1465A57DEA

Q37354846-3F2838DE-30EB-4056-A581-96808DDE7F44

Q37354846-4E8ABDAE-BAA7-4BCB-94FB-BB0FCB67C515

P304

Q37354846-6D78CE74-F053-42A3-BCE1-21EABA3118E2

P31

Q37354846-1BE20186-C53E-4022-9F82-1B6B1F807E95

P356

Q37354846-F84AA23E-9129-4F93-BD53-E116011A4575

P433

Q37354846-AF99DAE5-75A3-4CA0-B647-AD53B433B74D

P478

Q37354846-893FDEEA-8718-4280-82D7-C9F82A56D646

P50

Q37354846-29CF0E14-6670-49EE-A59B-544265A40008

P577

Q37354846-B508A513-0D6F-450C-9D74-926E011248C3

P5875

Q37354846-971AE7CF-016A-407E-90B0-A7DFB619446C

P698

Q37354846-3533A034-06A3-49A6-A90A-75F768F324F7

P921

Q37354846-13171A37-87AF-4735-9196-BF03CE0DE327

P932

Q37354846-D95FF377-5F09-44D0-A834-0811665AB684

P356

P1433

Journal of Cerebral Blood Flow & Metabolism

P1476

Dynamic MRI using iron oxide n ...... d treatment in a glioma model.

@en

P2093

Csanad G Varallyay

http://www.w3.org/2001/XMLSchema#string

James A Goodman

http://www.w3.org/2001/XMLSchema#string

Leslie L Muldoon

http://www.w3.org/2001/XMLSchema#string

Martin M Pike

http://www.w3.org/2001/XMLSchema#string

Seymur Gahramanov

http://www.w3.org/2001/XMLSchema#string

Xin Li

http://www.w3.org/2001/XMLSchema#string

Yingjen J Wu

http://www.w3.org/2001/XMLSchema#string

P2860

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging.

Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors.

Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.

Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.

Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models

Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?

P304

853-860

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JCBFM.2008.162

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Edward A. Neuwelt

P577

2009-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23785693

http://www.w3.org/2001/XMLSchema#string

P698

19142191

http://www.w3.org/2001/XMLSchema#string

P921

P932

2747492

http://www.w3.org/2001/XMLSchema#string